Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest Content
Archive
For authors
About
Podcasts
Search for this keyword
Advanced search
Close
More
Main menu
Latest Content
Archive
For authors
About
Podcasts
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
disease-modifying antirheumatic drugs (DMARDs)
Email alerts
disease-modifying antirheumatic drugs (DMARDs)
Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
Huifang
Liang
,
Raghava
Danwada
,
Dianlin
Guo
,
Jeffrey R
Curtis
,
Ryan D
Kilpatrick
,
Barbara
Hendrickson
,
Syed S
Islam
RMD Open
Sep 2019,
5
(2)
e001013;
DOI:
10.1136/rmdopen-2019-001013
Special collections
Guidelines, Recommendations and Consensus Statements
Press releases
(1)